论文部分内容阅读
目的探讨多发性骨髓瘤(MM)患者血清β2微球蛋白(β2-MG)和高敏C反应蛋白(hsCRP)的变化及其临床意义。方法采用胶乳增强免疫透射比浊法检测对150例MM患者(MM组)和50例正常体检者(对照组)的血清β2-MG和hsCRP水平,对比分析不同临床分期及治疗前后的血清β2-MG和hsCRP的变化。结果MM组血清β2-MG和hsCRP水平明显高于对照组,且随临床分期的增加依次增高,差异有统计学意义,均P<0.01。与治疗前相比,MM治疗有效组血清β2-MG和hsCRP水平明显下降,差异有统计学意义,均P<0.01(t=8.448,18.390),而治疗无效组则差异无统计学意义,均P>0.05(t=1.525,1.495)。结论血清β2-MG和hsCRP检测可用于MM患者的临床分期、疗效监测和预后判断。
Objective To investigate the changes of serum β2 microglobulin (β2-MG) and high-sensitivity C-reactive protein (hsCRP) in patients with multiple myeloma (MM) and its clinical significance. Methods Serum β2-MG and hsCRP levels were measured by latex enhanced immunoturbidimetry in 150 MM patients (MM group) and 50 normal controls (control group). The levels of serum β2-MG and hsCRP in different clinical stages and before and after treatment were compared and analyzed. MG and hsCRP changes. Results Serum levels of β2-MG and hsCRP in MM group were significantly higher than those in control group, and increased with the increase of clinical stage, the difference was statistically significant (P <0.01). Compared with those before treatment, the levels of serum β2-MG and hsCRP in MM-treated group were significantly decreased (P <0.01, t = 8.448 and 18.390, respectively), while there was no significant difference between the two groups P> 0.05 (t = 1.525, 1.495). Conclusion Serum β2-MG and hsCRP can be used in the clinical stage, efficacy monitoring and prognosis of MM patients.